90
Drug Price Scrutiny Intensifies Amidst New Transparency Efforts
Table of Contents
Washington D.C. – Pharmaceutical pricing is once again under intense scrutiny following the Biden administration’s recent implementation of provisions within the Inflation Reduction Act (IRA) allowing Medicare to negotiate prices for certain high-cost drugs, effective in 2026. This action follows years of public and political pressure, initially ignited in 2017 when then-President Donald Trump accused drug companies of “getting away with murder” due to elevated medication costs.
